Lysophosphatidic acid receptors in cancer pathobiology

Histology and Histopathology

Volumn 29, Issue 3, 2014, Pages 313-321

  Tsujiuchi, Toshifumi ^a   Araki, Mutsumi ^a   Hirane, Miku ^a   Dong, Yan ^a   Fukushima, Nobuyuki ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Cancer; Cell function; Gene alteration; LPA; LPA receptor

Indexed keywords

LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHOLIPID;

ANIMAL; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LYSOPHOSPHOLIPIDS; NEOPLASMS; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION;

EID: 84893479844     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Aoki J., Inoue A. and Okudaira S. (2008). Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta 1781, 513-518.
2. Chen P. and Parks W.C. (2009). Role of matrix metalloproteinases in epithelial migration. J. Cell Biochem. 108, 1233-1243.
3. Choi J.W. and Chun J. (2013). Lysophospholipids and their receptors in the cetral nervous system. Biochem. Biophys. Acta 1831, 20-32.
4. Choi J.W., Herr D.R., Noguchi K., Yung Y.C., Lee C.W., Mutoh T., Lin M.E., Teo S.T., Park K.E., Mosley A.N. and Chun J. (2010). LPA receptors: subtypes and biological actions. Anu. Rev. Pharmacol. Toxicol. 50, 157-186.
5. Contos J.J.A., Ishii I. and Chun J. (2000). Lysophosphatidic acid receptors. Mol. Pharmacol. 58, 1188-1196.
6. Contos J.J.A., Ishii I., Fukushima N., Kingsbury M.A., Ye X., Kawamura S., Brown J.H. and Chun J. (2002). Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell. Biol. 22, 6921-6929.
7. Fang X., Gaudette D. and Furui T. (2000). Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann. NY Acad. Sci. 905, 188-208.
8. Fang X., Schummer M., Mao M., Yu S., Tabassam F.H., Swaby R., Hasegawa Y., Tanyi J.L., LaPushin R., Eder A., Jaffe R., Erickson J. and Mills G.B. (2002). Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta 1582, 257-264.
9. Ferrara N., Gerber H.P. and LeCouter J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
10. Fishman D.A., Liu Y., Ellerbrock S.M. and Stack M.S. (2001). Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 61, 3194-3199.
11. Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
12. Fujita T., Miyamoto S., Onoyama I., Sonoda K., Mekada E. and Nakano H. (2003). Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett. 192, 161-169.
13. Fukui R., Tanabe E., Kitayoshi M., Yoshikawa K., Fukushima N. and Tsujiuchi T. (2012a). Negative regulation of cell motile and invasive activities by lysophosphatidic acid receptor-3 in colon cancer HCT116 cells. Tumor Biol. 33, 1899-1905.
14. Fukui R., Kato K., Okabe K., Kitayoshi M., Tanabe E., Fukushima N. and Tsujiuchi T. (2012b). Enhancement of drug resistance by lysophosphatidic acid receptor-3 in mouse mammary tumor FM3A cells. J. Toxicol. Pathol. 25, 225-228.
15. Fukushima N. (2004). LPA in neural cell development. J. Biol. Chem. 277, 45428-45434.
16. Furui T., LaPushin R., Mao M., Khan H., Watt S.R., Watt M.A.V., Lu Y., Fang X., Tsutsui S., Siddik Z.H., Bast R.C. Jr and Mills G.B. (1999). Overexpression of Edg-2/vzg-1 Induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clinical Cancer Res. 5, 4308-4318.
17. Furuta D., Yamane M., Tsujiuchi T., Moriyama R. and Fukushima N. (2012). lysophosphatidic acid induces neurite branch formation through LPA3. Mol. Cell. Neurosci. 50, 21-34.
18. Goetzl E.J., Dolezalova H., Kong Y., Hu Y.-L., Jaffe R.B., Kalli K.R. and Conover C.A. (1999). Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 59, 5370-5375.
19. Hayashi M., Okabe K., Yamawaki Y., Teranishi M., Honoki K., Mori T., Fukushima N. and Tsujiuchi T. (2011). Loss of lysophosphatidic acid receptor-3 enhances cell migration in rat lung tumor cells. Biochem. Biophys. Res. Commun. 405, 450-454.
20. Hayashi M. Okabe K., Kato K., Okumura M., Fukui R., Honoki K., Fukushima N. and Tsujiuchi T. (2012). Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. Cancer Lett. 316, 91-96.
21. Hu Y.-L., Tee M.-K., Goetzl E.J., Auersperg N., Mills G.B., Ferrara N. and Jaffe R.B. (2001). Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst. 93, 762-768.
22. Ishii I, Contos J.J.A., Fukushima N. and Chun J. (2000). Functional comparisons of the lysophosphatidic acid receptors, LPA1/VZG-1/EDG-2, LPA2/EDG-4, and LPA3/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol. Pharmacol. 58, 895-902.
23. Ishii I., Fukushima N., Ye X. and Chun J. (2004). Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73, 321-354.
24. Ishii S, Noguchi K. and Yanagida K. (2009). Non-Edg family lysophosphatidic acid (LPA) receptors. Prostaglandins Other Lipid Mediat. 89, 57-65.
25. Jeong K.J., Park S.Y., Cho K.H., Sohn J.S., Lee J., Kim Y.K., Kang J. Park C.G., Han J.W. and Lee H.Y. (2012). The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 31, 4279-4289.
26. Jiao J., Pienkowska M., Glickman B.W. and Zielenska M. (1996). Molecular analysis of mutations induced by ethylationg N-nitroso compounds in the lacI gene of Escherichia coli. Mutat. Res. 352, 39-45.
27. Jones P.A. (2002). DNA methylation and cancer. Oncogene 21, 5358-5360.
28. Jones P.A. and Baylin S.B. (2002). The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415-428.
29. Jones P.A. and Baylin S.B. (2007). The epigenomics of cancer. Cell 128, 683-692.
30. Kamiya H., Miura H., Murata-Kamiya N., Ishikawa H., Sakaguchi T., Inoue H., Sasaki T., Masutani C., Hanaoka F. and Nishimura S. (1995). 8-Hydroxyadenine (7,8-dihydro-8-oxoadenine) induces misincorporation in in?vitro DNA synthesis and mutations in NIH3T3 cells. Nucleic Acids Res. 23, 2893-2899.
31. Kato K., Yoshikawa K., Tanabe E., Kitayoshi M., Fukui R., Fukushima N. and Tsujiuchi T. (2012a). Opposite roles of LPA1 and LPA3 on cell motile and invasive activities of pancreatic cancer cells. Tumor Biol. 33, 1739-1744.
32. Kato K., Fukui R., Okabe K., Tanabe E., Kitayoshi M., Fukushima N. and Tsujiuchi T. (2012b). Constitutively active lysophosphatidic acid receptor-1 enhances the induction of matrix metalloproteinase-2. Biochem. Biophys. Res. Commun. 417, 790-793.
33. Kessenbrock K., Plaks V. and Werb Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
34. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S. and Ferrara N. (1993). Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844.
35. Kitada H., Tsutsumi M., Tsujiuchi T., Takahama M., Fukuda T., Narita N. and Konishi Y. (1996). Frequent mutations of Ki-ras but no mutations oh Ha-ras and p53 in lung lesions induced by Nnitrosobis(2-hydroxypropyl)amine in rats. Mol. Carcinog. 15, 276-283.
36. Kitayama J., Shida D., Sako A., Ishikawa M., Hama K., Aoki J., Arai H. and Nagawa H. (2004). Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 6, R640-R646.
37. Kitayoshi M., Kato K., Tanabe E., Yoshikawa K., Fukui R., Fukushima N. and Tsujiuchi T. (2012). Enhancement of endothelial cell migration by constitutively active LPA1-expressing tumor cells. Biochem. Biophys. Res. Commun. 422, 339-343.
38. Lin M-E, Herr D.R. and Chun J. (2010). Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 91, 130-138.
39. Malins D.C. and Haimanot R. (1990). 4,6-Diamino-5-formamidopyrimidine, 8-hydroxyguanine and 8-hydroxyadenine in DNA from neoplastic liver of English sole exposed to carcinogens. Biochem. Biophys. Res. Commun. 173, 614-619.
40. Moriya M., Ou C., Bodepudi V., Johnson F., Takeshita M. and Grollma A.P. (1991). Site-specific mutagenesis using a gapped duplex vector: a study of translation synthesis past 8-oxodeoxyguanosine in E. coli. Mutat. Res. 254, 281-288.
41. Murakami Y., Hayashi K. and Sekiya T. (1991). Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis Cancer Res. 51, 3356-3361.
42. Nakae D., Yoshiji H., Mizumoto Y., Horiguchi K., Shiraiwa K., Tamura K., Denda A. and Konishi Y. (1992). High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats, Cancer Res. 52, 5042-5054.
43. Obo Y., Yamada T., Furukawa M., Hotta M., Honoki K., Fukishima N. and Tsujiuchi T. (2009). Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat. Res. 660, 47-50.
44. Ohashi K., Tsutsumi M., Tsujiuchi T., Kobitsu K., Okajima E., Nakajima Y., Nakano H., Takahashi M., Mori Y. and Konishi Y. (1996). Enhancement of N-nitrosodiethylamine-initiated hepatocarcinogenesis caused by a colchicines-induced cell cycle disturbance in partially hepatectomized rats. Cancer Res. 56, 3437-3479.
45. Okabe K., Hayashi M., Fujii M., Honoki K., Mori T., Fukushima N. and Tsujiuchi T. (2010a). Mutations of lysophosphatidic acid receptor genes in human osteosarcoma cells. Pathobiology 77, 278-282.
46. Okabe K., Hayashi M., Wakabayashi N., Yamawaki Y., Teranishi M., Fukushima N. and Tsujiuchi T. (2010b). Different expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in mouse tumor cells. Pathobiology 77, 309-314.
47. Okabe K., Hayashi M., Yamawaki Y., Teranishi M., Honoki K., Mori T., Fukushima N. and Tsujiuchi T. (2011). Possible involvement of lysophosphatidic acid receptor-5 gene in the acquisition of growth advantage of rat tumor cells. Mol. Carcinog. 50, 635-642.
48. Okabe K, Hayashi M., Kato K., Okumura M., Fukui R., Honoki K., Fukushima N. and Tsujiuchi T. (2013). Lysophosphatidic acid receptor-3 increases tumorigenicity and aggressiveness of rat hepatoma RH7777 cells. Mol. Carcinog. 52, 247-254.
49. Park S.Y., Jeong K.J., Panupinthu N., Yu S., Lee J., Han J.W., Kim J.M., Lee J-S., Kang J., Park C.G., Mills G.B. and Lee H.Y. (2011). Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 30, 1351-1359.
50. Pustilnik T.B., Estrella V., Wiener J.R., Mao M., Eder A., Watt M.A.V., Bast R.C. Jr and Mills G.B. (1999). Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin. Cancer Res. 5, 3704-3710.
51. Sardar V.M., Bautista D.L., Fischer D.J., Yokoyama K., Nusser N., Viraq T., Wang D.A., Baker D.L., Tiqyi G. and Parrill A.L. (2002). Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim. Biophys. Acta 1582, 309-317.
52. Sau A., Tregno F.P., Valentino F., Federici G. and Caccuri A.M. (2010). Glutathione transferases and development of new principles to overcome drug resistance. Arch. Biochem. Biophys. 500, 116-122.
53. Schulte K.M., Beyer A., Köhrer K., Oberhäuser S. and Röher H.D. (2001). Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int. J. Cancer 92, 249-256.
54. Shano S., Hatanaka K., Ninose S., Moriyama R., Tsujiuchi T. and Fukushima N. (2008). A Lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation. Biochim. Biophys. Acta 1783: 748-759.
55. Shida D., Kitayama J., Yanaguchi H., Okaji Y., Tsuno N.H., Watanabe T., Takuwa Y. and Nagawa H. (2003). Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 63,1706-1711.
56. Shida D., Kitayama J., Yamaguchi H., Hama K., Aoki J., Arai H., Yamashita H., Mori K., Sako A., Konishi T., Watanabe T., Sakai T., Suzuki R., Ohta H., Takuwa Y. and Nagawa H. (2004a). Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp. Cell Res. 301, 168-178.
57. Shida D., Watanabe T., Aoki J., Hama K., Kitayama J., Sonoda H., Kishi Y., Yamaguchi H., Sasaki S., Sako A., Konishi T., Arai H. and Nagawa H. (2004b). Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab. Invest. 84,1352-1362.
58. Szakács G., Paterson J.K., Ludwig J.A., Booth-Genthe C. and Gottesman M.M. (2006). Targeting multidrug resistance in cancer. Nat. Rev. Drug. Discov. 5, 219-234.
59. Tabata K, Baba K, Shiraishi A, Ito M. and Fujita N. (2007). The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 363, 861-866.
60. Tanabe E., Kitayoshi M., Yoshikawa K., Shibata A., Honoki K., Fukushima N. and Tsujiuchi T. (2012). Loss of lysophosphatidic acid receptor-3 suppresses cell migration activity of human sarcoma cells. J. Recept. Signal Transduct. Res. 32, 328-334.
61. Tanabe E., Kitayoshi M., Hirane M., Araki M., Dong Y., Fukushima N. and Tsujiuchi T. (2013). Downregulation of activation factors of endothelia and fibroblasts via lysophosphatidic acid signaling in a mouse lung cancer LL/2 cell line. J. Recept. Signal Transduct. Res. 33, 286-290.
62. Tsujino M., Fujii M., Okabe K., Mori T., Fukushima N. and Tsujiuchi T. (2010). Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch. 457, 669-676.
63. Tsujiuchi T., Shimizu K., Onishi M., Shigemura M., Shano S., Honoki K. and Fukushima N. (2006a). Aberrant expressions of lysophosphatidic acid receptor genes in lung and liver tumors of rats. J. Toxicol. Pathol. 19, 137-141.
64. Tsujiuchi T., Shimizu K., Onishi M., Sugata E., Fujii H., Mori T., Honoki K. and Fukushima N. (2006b). Involvement of aberrant DNA methylation on reduced expression of lysophosphatidic acid receptor-1 gene in rat tumor cell lines. Biochem. Biophys. Res. Commun. 349, 1151-1155.
65. Tsujiuchi T., Furukawa M., Yamasaki A., Hotta M., Kusunoki C., Suyama N., Mori T., Honoki K. and Fukushima N. (2009). Infrequent mutation of lysophosphatidic acid receptor-1 gene in hamster pancreatic duct adenocarcinomas and established cell lines. J. Toxicol. Pathol. 22, 89-92.
66. Tsujiuchi T., Okabe K. and Fukushima N. (2011). Genetic and epigenetic alterations of lysophosphatidic acid receptor genes in rodent tumors by experimental models. J. Toxicol. Pathol. 24, 143-148.
67. Tsutsumi M., Murakami Y., Kondoh S., Tsujiuchi T., Honoki K., Horiguchi K., Noguchi O., Kobayashi E., Okita S., Sekiya T. and Konishi Y. (1993). Comparison of K-ras oncogene activation in pancreatic duct carcinomas and cholangiocarcinomas induced in hamsters by N-nitrosobis(2-oxopropyl)amine. Jpn. J. Cancer Res. 84, 956-960.
68. Valentine W.J., Fells J.I., Perygin D.H., Mujahid S., Yokoyama K., Fujiwara Y., Tsukahara R., Van Brocklyn J.R., Parrill A.L. and Tiqyi G. (2008). Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors. J. Boil. Chem. 283, 12175-12187.
69. Wakabayashi N., Tsujino M., Tajiri M., Taki M., Koshino A., Ikeda H., Fukushima N. and Tsujiuchi T. (2010). No mutations of lysophosphatidic acid receptor genes in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats. J. Toxicol. Pathol. 3, 63-66.
70. Wang D., Kreutzer D.A. and Essigmann J.M. (1998). Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. Mutat. Res. 400, 99-115.
71. Xu Y., Gaudette D.C., Boynton J.D., Frankel A., Fang X.-J., Sharme A., Hurteau J., Casey G., Goodbody A., Mellors A., Holub B.J. and Mills G.B. (1995). Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1, 1223-1232.
72. Yamada T., Furukawa M., Hotta M., Yamasaki A., Honoki K., Fukushima N. and Tsujiuchi T. (2009). Mutations of lysophosphatidic acid receptor-1 gene during progression of lung tumors in rats. Biochem. Biophys. Res. Commun. 378, 424-427.
73. Yu S., Murph M.M., Lu Y., Liu S., Hall H.S., Liu J., Stephens C., Fang X. and Mills G.B. (2008). Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl. Cancer Inst. 100, 1630-1642.
74. Zaslavsky A., Singh L.S., Tan H., Ding H., Liang Z. and Xu Y. (2006). Homo-and hetero-demerization of LPA/SIP receptors, OGR1 and GPR4. Biochim. Biophys. Acta 1761, 1200-1212.